Drug Trial Radar · NCT06551142
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
845
Planned (sponsor's estimate)
Start
Sep 30, 2024
Primary completion
Oct 16, 2028
Study completion Jun 8, 2029
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab, tarlatamab, dostarlimab
Conditions
- Neoplasms
Interventions
Ris-RezBiological
Ris-Rez will be administered
CisplatinDrug
Cisplatin will be administered
CarboplatinDrug
Carboplatin will be administered
AtezolizumabBiological
Atezolizumab will be administered
PembrolizumabBiological
Pembrolizumab will be administered
DurvalumabBiological
Durvalumab will be administered
CetuximabBiological
Cetuximab will be administered
BevacizumabBiological
Bevacizumab will be administered
TarlatamabBiological
Tarlatamab will be administered
DostarlimabBiological
Dostarlimab will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Number of participants with Adverse Events (AEs)Time frame: Up to approximately 28 months
- Phase 1a: Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 21 days
- Phase 1a: Number of participants with AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs) by severityTime frame: Up to approximately 30 months
- Phase 1a: Number of participants with AEs leading to dose modificationsTime frame: Up to approximately 28 months
- Phase 1a: Number of participants with changes in vital signs, body weight, laboratory tests, electrocardiogram (ECG) and Eastern Cooperative Oncology Group (ECOG) performance statusTime frame: Up to approximately 28 months
- Phase 1b: Confirmed Objective Response Rate (cORR)Time frame: Up to approximately 27 months
Locations
67 sites in 13 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Stanford, California · Recruiting
GSK Investigational Site
Denver, Colorado · Recruiting
GSK Investigational Site
New Haven, Connecticut · Recruiting
GSK Investigational Site
Fort Wayne, Indiana · Recruiting
GSK Investigational Site
Boston, Massachusetts · Recruiting
GSK Investigational Site
Detroit, Michigan · Recruiting
GSK Investigational Site
New Brunswick, New Jersey · Recruiting
GSK Investigational Site
Myrtle Beach, South Carolina · Recruiting
GSK Investigational Site
Nashville, Tennessee · Recruiting
GSK Investigational Site
Austin, Texas · Recruiting
GSK Investigational Site
Dallas, Texas · Recruiting
GSK Investigational Site
San Antonio, Texas · Recruiting
GSK Investigational Site
Tyler, Texas · Recruiting
GSK Investigational Site
West Valley City, Utah · Recruiting
GSK Investigational Site
Norfolk, Virginia · Recruiting
GSK Investigational Site
Rosario, Argentina · Completed
GSK Investigational Site
Viedma, Argentina · Recruiting
GSK Investigational Site
Hamilton, Ontario, Canada · Recruiting
GSK Investigational Site
Ottawa, Ontario, Canada · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Sherbrooke, Quebec, Canada · Recruiting
GSK Investigational Site
Bordeaux, France · Recruiting
GSK Investigational Site
Lyon, France · Recruiting
GSK Investigational Site
Villejuif, France · Recruiting
GSK Investigational Site
Pokfulam, Hong Kong · Recruiting
GSK Investigational Site
Shatin, Hong Kong · Recruiting
GSK Investigational Site
Jerusalem, Israel · Recruiting
GSK Investigational Site
Jerusalem, Israel · Recruiting
GSK Investigational Site
Ramat Gan, Israel · Recruiting
GSK Investigational Site
Tel Aviv, Israel · Recruiting
GSK Investigational Site
Milan, Italy · Recruiting
GSK Investigational Site
Naples, Italy · Recruiting
GSK Investigational Site
Roma, Italy · Recruiting
GSK Investigational Site
Verona, Italy · Recruiting
GSK Investigational Site
Aichi, Japan · Recruiting
GSK Investigational Site
Chiba, Japan · Recruiting
GSK Investigational Site
Shizuoka, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.